Nama's AI scorecard currently rates Cencora Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is COR's P/E ratio?

Cencora trades at a trailing price-to-earnings ratio of 18.6.

When does COR report earnings?

Cencora's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $4.55.

What is the COR price target?

The median analyst price target from 12 analysts is $376.00, with a range of $330.00 – $400.00.

Is COR Shariah compliant?

Nama's AAOIFI-style screen reads Cencora as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does COR pay a dividend?

Yes — Cencora's dividend yield is 0.7%.

Nama Insights

Cencora (COR)

Healthcare · Medical Distribution · NYSE

S&P 500

Cencora (COR) is a Healthcare company in the Medical Distribution industry. It has a market capitalization of $63.65B, a trailing price-to-earnings ratio of 18.6 and a free-cash-flow yield of 4.9%. Over the most recent reported fiscal year, revenue grew 9.3% and free cash flow per share grew 9.8%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Lagging · -11.9% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-11.7%

How far the last close sits under the highest price of the past five years.

Market cap	$63.65B
Trailing P/E	18.6
Price / book	20.9
Price / sales	0.2
FCF yield	4.9%
Dividend yield	0.7%
Gross margin	4.0%
Operating margin	1.4%
Net margin	0.8%
Revenue growth (YoY)	+9.3%
Revenue growth (3-yr annual)	+10.4%
EPS growth (YoY)	+16.2%
FCF/share growth (YoY)	+9.8%
Beta	0.6
Exchange	NYSE
Sector	Healthcare
Industry	Medical Distribution

COR earnings

Next report: Feb 3, 2027 (Q1 2027, EPS estimate $4.55). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q4 2026	Nov 4, 2026	$4.66	$4.57	+2.0%	—
Q3 2026	Aug 5, 2026	$4.48	$4.34	+3.2%	$84.75B
Q2 2026	May 6, 2026	$4.75	$4.73	+0.4%	$78.36B
Q1 2026	Feb 4, 2026	$4.08	$4.04	+1.0%	$85.93B

COR analyst price target

Median target $376.00 from 12 analysts, ranging $330.00 – $400.00.

Medical Distribution peers

Ticker	Company	Market cap	P/E
MCK	McKesson	$122.48B	24.9
CAH	Cardinal Health	$62.92B	23.3
HSIC	Henry Schein	$9.51B	16.2
AHG	Akso Health Group	$1.16B	—

Explore live COR data on Nama Insights →

Recent Congressional trades

Cencora trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Jared Moskowitz	House	Sell	$1,001 - $15,000	Jun 19, 2026
Jared Moskowitz	House	Buy	$1,001 - $15,000	Apr 30, 2026
Jared Moskowitz	House	Buy	$1,001 - $15,000	Apr 30, 2026
Greg Landsman	House	Sell	$15,001 - $50,000	Apr 8, 2025
Greg Landsman	House	Buy	$15,001 - $50,000	Aug 14, 2024

COR FAQ

Is COR a buy?: Nama's AI scorecard currently rates Cencora Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is COR's P/E ratio?: Cencora trades at a trailing price-to-earnings ratio of 18.6.
When does COR report earnings?: Cencora's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $4.55.
What is the COR price target?: The median analyst price target from 12 analysts is $376.00, with a range of $330.00 – $400.00.
Is COR Shariah compliant?: Nama's AAOIFI-style screen reads Cencora as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does COR pay a dividend?: Yes — Cencora's dividend yield is 0.7%.